Skip to main content

Advertisement

SpringerLink
Log in

Management of Esophageal Squamous Cell Carcinoma with Definitive Chemoradiotherapy in a Patient with Scleroderma: Case Report and Review of the Literature

  • Case Report
  • Published:
Journal of Gastrointestinal Cancer Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Abbreviations

PET:

Positron emission tomography

FDG:

Fluorodeoxyglucose

SUV:

Standardized uptake value

CT:

Computed tomography

AUC:

Area under the curve

GTV:

Gross tumor volume

CTV:

Clinical target volume

PTV:

Planning target volume

RTOG:

Radiation Therapy Oncology Group

EORTC:

European Organization for Research and Treatment of Cancer

References

  1. Farmer RG, Gifford Jr RW, Hines Jr EA. Prognostic significance of Raynaud's phenomenon and other clinical characteristics of systemic scleroderma. A study of 271 cases. Circulation. 1960;21:1088–95.

    Article  PubMed  CAS  Google Scholar 

  2. Duncan SC, Winkelmann RK. Cancer and scleroderma. Arch Dermatol. 1979;115(8):950–5.

    Article  PubMed  CAS  Google Scholar 

  3. Abu-Shakra M, Guillemin F, Lee P. Cancer in systemic sclerosis. Arthritis Rheum. 1993;36(4):460–4.

    Article  PubMed  CAS  Google Scholar 

  4. Chatterjee S, et al. Risk of malignancy in scleroderma: a population-based cohort study. Arthritis Rheum. 2005;52(8):2415–24.

    Article  PubMed  Google Scholar 

  5. Derk CT, et al. A cohort study of cancer incidence in systemic sclerosis. J Rheumatol. 2006;33(6):1113–6.

    PubMed  Google Scholar 

  6. Derk CT, et al. Increased incidence of carcinoma of the tongue in patients with systemic sclerosis. J Rheumatol. 2005;32(4):637–41.

    PubMed  Google Scholar 

  7. Peters-Golden M, et al. Incidence of lung cancer in systemic sclerosis. J Rheumatol. 1985;12(6):1136–9.

    PubMed  CAS  Google Scholar 

  8. Rosenthal AK, et al. Incidence of cancer among patients with systemic sclerosis. Cancer. 1995;76(5):910–4.

    Article  PubMed  CAS  Google Scholar 

  9. Roumm AD, Medsger Jr TA. Cancer and systemic sclerosis. An epidemiologic study. Arthritis Rheum. 1985;28(12):1336–40.

    Article  PubMed  CAS  Google Scholar 

  10. Ribeiro Jr U, et al. Risk factors for squamous cell carcinoma of the oesophagus. Br J Surg. 1996;83(9):1174–85.

    Article  PubMed  Google Scholar 

  11. Wipff J, et al. Prevalence of Barrett's esophagus in systemic sclerosis. Arthritis Rheum. 2005;52(9):2882–8.

    Article  PubMed  CAS  Google Scholar 

  12. Katzka DA, et al. Barrett's metaplasia and adenocarcinoma of the esophagus in scleroderma. Am J Med. 1987;82(1):46–52.

    Article  PubMed  CAS  Google Scholar 

  13. Marie I, et al. Oesophageal mucosal involvement in patients with systemic sclerosis receiving proton pump inhibitor therapy. Aliment Pharmacol Ther. 2006;24(11–12):1593–601.

    Article  PubMed  CAS  Google Scholar 

  14. Kang KY, et al. Incidence of cancer among patients with systemic sclerosis in Korea: results from a single centre. Scand J Rheumatol. 2009;38(4):299–303.

    Article  PubMed  CAS  Google Scholar 

  15. NCCN (version 2.2011) NCCN Clinical Practice Guidelines in Oncology: Esophageal and Esophagogastric Junction Cancers

  16. Morrow M, et al. Standard for breast conservation therapy in the management of invasive breast carcinoma. CA Cancer J Clin. 2002;52(5):277–300.

    Article  PubMed  Google Scholar 

  17. Gaast, A.V., et al., Effect of preoperative concurrent chemoradiotherapy on survival of patients with resectable esophageal or esophagogastric junction cancer: results from a multicenter randomized phase III study. J Clin Oncol, 2010. 28(15 s): p. suppl; abstr 4004.

    Google Scholar 

  18. RTOG. RTOG/EORTC Late Radiation Morbidity Scoring Scheme. [2/18/2011]; Available from: www.rtog.org/members/toxicity/late.html.

  19. Varga J, et al. Exaggerated radiation-induced fibrosis in patients with systemic sclerosis. JAMA. 1991;265(24):3292–5.

    Article  PubMed  CAS  Google Scholar 

  20. Ross JG, et al. Acute and late reactions to radiation therapy in patients with collagen vascular diseases. Cancer. 1993;71(11):3744–52.

    Article  PubMed  CAS  Google Scholar 

  21. Morris MM, Powell SN. Irradiation in the setting of collagen vascular disease: acute and late complications. J Clin Oncol. 1997;15(7):2728–35.

    PubMed  CAS  Google Scholar 

  22. Gold DG, et al. Radiotherapy for malignancy in patients with scleroderma: the Mayo Clinic experience. Int J Radiat Oncol Biol Phys. 2007;67(2):559–67.

    Article  PubMed  Google Scholar 

  23. Lin A, et al. Toxicity of radiotherapy in patients with collagen vascular disease. Cancer. 2008;113(3):648–53.

    Article  PubMed  Google Scholar 

  24. Gold DG, et al. Chronic toxicity risk after radiotherapy for patients with systemic sclerosis (systemic scleroderma) or systemic lupus erythematosus: association with connective tissue disorder severity. Radiother Oncol. 2008;87(1):127–31.

    Article  PubMed  Google Scholar 

  25. Patel AA, et al. Implications of respiratory motion as measured by four-dimensional computed tomography for radiation treatment planning of esophageal cancer. Int J Radiat Oncol Biol Phys. 2009;74(1):290–6.

    Article  PubMed  Google Scholar 

  26. Vlachaki M, et al. Impact of respiratory gating using 4-dimensional computed tomography on the dosimetry of tumor and normal tissues in patients with thoracic malignancies. Am J Clin Oncol. 2009;32(3):262–8.

    Article  PubMed  Google Scholar 

Download references

Competing Interests

The authors declare that they have no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Radiation Oncology, Columbia University Medical Center—New York Presbyterian Hospital, New York, NY, USA

    David P. Horowitz

  2. Department of Medicine, Columbia University Medical Center—New York Presbyterian Hospital, New York, NY, USA

    Balazs Halmos & John Poneros

  3. Department of Surgery, Columbia University Medical Center—New York Presbyterian Hospital, New York, NY, USA

    Joshua Sonett

  4. Department of Pathology, Columbia University Medical Center—New York Presbyterian Hospital, New York, NY, USA

    Helen Remotti

  5. Winter Park Cancer Center, Winter Park, FL, USA

    Ryan J. Burri

Authors
  1. David P. Horowitz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Balazs Halmos
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. John Poneros
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Joshua Sonett
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Helen Remotti
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ryan J. Burri
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ryan J. Burri.

Additional information

Consent

Written informed consent was obtained from the patient for publication of the case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Horowitz, D.P., Halmos, B., Poneros, J. et al. Management of Esophageal Squamous Cell Carcinoma with Definitive Chemoradiotherapy in a Patient with Scleroderma: Case Report and Review of the Literature. J Gastrointest Canc 43 (Suppl 1), 156–160 (2012). https://doi.org/10.1007/s12029-012-9393-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12029-012-9393-2

Keywords

Search

Navigation